altimmune glp-1 Altimmune, Inc. Announces Presentation of IMPACT Phase 2b Study Results at EASL Congress 2026, Highlighting Efficacy and Safety Data for Pemvidutide in MASH Altimmune (ALT): Odd drug out
Pay in 4 interest-free payments of $5.72 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31

























